ReviewBladder (San Francisco, Calif.)2025
Diagnostic accuracy of the Vesical Imaging Reporting and Data System for muscle-invasive bladder cancer and its role in reducing repeat transurethral resection of bladder tumor: A systematic review.
Review in Bladder (San Francisco, Calif.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Vesical Imaging Reporting and Data System (VI-RADS) has been introduced as a standardized tool for assessing multiparametric magnetic resonance imaging (MRI) in the pre-operative staging of bladder cancer. Objective: The present systematic review evaluates the efficacy of VI-RADS in diagnosing muscle-invasive bladder cancer (MIBC) compared with established diagnostic techniques. A systematic review was conducted according to PRISMA guidelines using PubMed, Scopus, and Web of Science. Studies assessing VI-RADS for MIBC diagnosis were included if they reported sensitivity, specificity, area under the curve, and comparisons with conventional approaches. Study characteristics, sample size, VI-RADS cutoff, diagnostic performance, and risk of bias were evaluated. Thirteen studies (sample sizes ranging from 18 to 340) demonstrated high diagnostic performance, with sensitivity ranging from 78% to 100%, specificity from 73% to 96%, and AUC from 0.86 to 0.96. VI-RADS outperformed standard assessment in reducing transurethral resection of bladder tumor (TURBT)-related understaging. A forest plot showed variability in sensitivity, influenced by radiologist experience, magnetic resonance imaging protocols, and study design. The risk of bias was moderate-to-low. Conclusion: VI-RADS is an effective non-invasive tool for detecting MIBC and plays an important role in pre-operative decision-making. It may reduce the need for repeat TURBT. Standardization of MRI protocols and radiologist training is vital to improve diagnostic reliability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.